the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children

Beta Thalassemia Major Clinical Trial

Official title:

the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02674607
• Other study ID #: 2132/10/13
• Status: Completed
• Phase: N/A
• First received: February 1, 2016
• Last updated: October 24, 2017
• Start date: October 2015
• Est. completion date: October 2017

Study information

• Verified date: October 2017
• Source: Tanta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the possible immunologic effects of spirulina in children with beta thalassemia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Years to 18 Years

Eligibility

Inclusion Criteria:

• children with thalassemia major

Exclusion Criteria:

• children with other chronic hemolytic anemias

Related Conditions & MeSH terms

• Beta Thalassemia Major
• beta-Thalassemia
• Thalassemia

Intervention

Dietary Supplement:
• Spirulina

Locations

Country	Name	City	State
Egypt	Faculty of Medicine- Tanta University	Tanta	Gharbia

Sponsors (1)

Lead Sponsor	Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cluster of differentiation (CD4/CD25) ratio		3 months
Primary	cluster of differentiation (CD33/CD11b/Lin) ratio		3 months
Primary	serum immunoglobulins levels		3 months
Primary	serum levels of interferon gamma		3 months